|
1
|
Manning G, Whyte DB, Martinez R, Hunter T
and Sudarsanam S: The protein kinase complement of the human
genome. Science. 298:1912–1934. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Podolsky DK: Inflammatory bowel disease. N
Engl J Med. 347:417–429. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Matricon J, Barnich N and Ardid D:
Immunopathogenesis of inflammatory bowel disease. Self Nonself.
1:299–309. 2010. View Article : Google Scholar
|
|
4
|
Strober W, Fuss I and Mannon P: The
fundamental basis of inflammatory bowel disease. J Clin Investig.
117:514–521. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Cominelli F: Cytokine-based therapies for
Crohn's disease-New paradigms. N Engl J Med. 351:2045–2048. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lv QK, Liu JX, Li SN, Gao YJ, Lv Y, Xu ZP,
Huang BX, Xu SY, Yang DX, Zeng YL, et al: Mycophenolate mofetil
modulates differentiation of Th1/Th2 and the secretion of cytokines
in an active crohn's disease mouse model. Int J Mol Sci.
16:26654–26666. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Orenstein R: Anti-interleukin-12 antibody
for active Crohn's disease. N Engl J Med. 352:627–628. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sartor RB: Mechanisms of disease:
Pathogenesis of Crohn's disease and ulcerative colitis. Nat Clin
Pract Gastroenterol Hepatol. 3:390–407. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Luo JH, Zhang CY, Lu CY, Guo GH, Tian YP
and Li YL: Serum expression level of cytokine and chemokine
correlates with progression of human ovarian cancer. Eur J Gynaecol
Oncol. 38:33–39. 2017.PubMed/NCBI
|
|
10
|
Atreya I, Atreya R and Neurath MF:
NF-kappaB in inflammatory bowel disease. J Intern Med. 263:591–596.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kyriakis JM and Avruch J: Mammalian
mitogen-activated protein kinase signal transduction pathways
activated by stress and inflammation. Physiol Rev. 81:807–869.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kim EK and Choi EJ: Pathological roles of
MAPK signaling pathways in human diseases. Biochim Biophys Acta.
1802:396–405. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Mi Y, Zhang D, Jiang W, Weng J, Zhou C,
Huang K, Tang H, Yu Y, Liu X, Cui W, et al: miR-181a-5p promotes
the progression of gastric cancer via RASSF6-mediated MAPK
signalling activation. Cancer Lett. 389:11–22. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Liao T, Wen D, Ma B, Hu JQ, Qu N, Shi RL,
Liu L, Guan Q, Li DS and Ji QH: Yes-associated protein 1 promotes
papillary thyroid cancer cell proliferation by activating the
ERK/MAPK signaling pathway. Oncotarget. 8:11719–11728. 2017.
View Article : Google Scholar :
|
|
15
|
Docena G, Rovedatti L, Kruidenier L,
Fanning A, Leakey NAB, Knowles CH, Lee K, Shanahan F, Nally K,
Mclean PG, et al: Down-regulation of p38 mitogen-activated protein
kinase activation and proinflammatory cytokine production by
mitogen-activated protein kinase inhibitors in inflammatory bowel
disease. Clin Exp Immunol. 162:108–115. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hommes D, van den Blink B, Plasse T,
Bartelsman J, Xu C, Macpherson B, Tytqat G, Peppelenbosch M and Van
Deventer S: Inhibition of stress-activated MAP kinases induces
clinical improvement in moderate to severe Crohn's disease.
Gastroenterology. 122:7–14. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wen JY and Chen ZW: Protective effect of
pharmacological preconditioning of total flavones of Abelmoschl
manihot on cerebral ischemic reperfusion injury in rats. Am J Chin
Med. 35:653–661. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lai X, Liang H, Zhao Y and Wang B:
Simultaneous determination of seven active flavonols in the flowers
of Abelmoschus manihot by HPLC. J Chromatogr Sci. 47:206–210. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang XR, Zhou ZH, Du AQ and Huang ZM:
Studies on the flavonol constituents of Abelmoschus manihot L.
Medic Chin J Nat Med. 2:91–93. 2004.
|
|
20
|
Fan L, Dong LY, Chen ZW, Cen DY, Jiang Q
and Ma CG: Analgesic effect of total flavone of Abelmoschl manihot
L Medic. Pharmacol Clin Chin Mater Med. 19:12–14. 2003.
|
|
21
|
Zhou L, An XF, Teng SC, Liu JS, Shang WB,
Zhang AH, Yuan YG and Yu JY: Pretreatment with the total flavone
glycosides of flos Abelmoschus manihot and hyperoside prevents
glomerular podo-cyte apoptosis in streptozotocin-induced diabetic
nephropathy. J Med Food. 15:461–468. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Gao S, Fan L, Dong LY, Zhao WZ and Chen
ZW: Effect of TFA on cell apoptosis in MCAO rats. Chin Pharmacol
Bull. 19:704–707. 2003.
|
|
23
|
Gu P, Zhu L, Liu Y, Zhang L, Liu J and
Shen H: Protective effects of paeoniflorin on TNBS-induced
ulcerative colitis through inhibiting NF-kappaB pathway and
apoptosis in mice. Int Immunopharmacol. 50:152–160. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhu L, Gu P and Shen H: Protective effects
of berberine hydrochloride on DSS-induced ulcerative colitis in
rats. Int Immunopharmacol. 68:242–251. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhu L, Gu P and Shen H: Gallic acid
improved inflammation via NF-κB pathway in TNBS-induced ulcerative
colitis. Int Immunopharmacol. 67:129–137. 2019. View Article : Google Scholar
|
|
26
|
Fu K, Lv X, Li W, Wang Y, Li H, Tian W and
Cao R: Berberine hydrochloride attenuates
lipopolysaccharide-induced endome-tritis in mice by suppressing
activation of NF-κB signal pathway. Int Immunopharmacol.
24:128–132. 2015. View Article : Google Scholar
|
|
27
|
Lee JC, Biasci D, Roberts R, Gearry RB,
Mansfield JC, Ahmad T, Prescott NJ, Satsangi J, Wilson DC, Jostins
L, et al: Genome-wide association study identifies distinct genetic
contributions to prognosis and susceptibility in Crohn's disease.
Nat Genet. 49:262–268. 2017. View
Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wu F, Guo NJ, Tian H, Marohn M, Gearhart
S, Bayless TM, Brant SR and Kwon JH: Peripheral blood MicroRNAs
distinguish active ulcerative colitis and Crohn's disease. Inflamm
Bowel Dis. 17:241–250. 2011. View Article : Google Scholar
|
|
29
|
Gałecki P, Gałecka E, Maes M, Chamielec M,
Orzechowska A, Bobińska K, Lewiński A and Szemraj J: The expression
of genes encoding for COX-2, MPO, iNOS, and sPLA2-IIA in patients
with recurrent depressive disorder. J Affect Disord. 138:360–366.
2012. View Article : Google Scholar
|
|
30
|
Nunberg MY, Werner L, Kopylov U, Haberman
Y, Lahad A, Weiss B and Shouval DS: Impaired IL-10 receptor
mediated suppression in monocyte from patients with Crohn's
disease. J Pediatr Gastroenterol Nutr. 66:779–784. 2018. View Article : Google Scholar
|
|
31
|
Okayasu I, Hatakeyama S, Yamada M, Ohkusa
T, Inagaki Y and Nakaya R: A novel method in the induction of
reliable experimental acute and chronic ulcerative colitis in mice.
Gastroenterology. 98:694–702. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Pan T, Guo HY, Zhang H, Liu AP, Wang XX
and Ren FZ: Oral administration of Lactobacillus paracasei
alleviates clinical symptoms of colitis induced by dextran sulphate
sodium salt in BALB/c mice. Benef Microbes. 5:315–322. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Dou W, Zhang J, Ren G, Ding L, Sun A, Deng
C, Wu X, Wei X, Mani S and Wang Z: Mangiferin attenuates the
symptoms of dextran sulfate sodium-induced colitis in mice via
NF-κB and MAPK signaling inactivation. Int Immunopharmacol.
23:170–178. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lian L, Huang Q, Zhang L, Qin H, He X, He
X, Ke J, Xie M and Lan P: Anti-fibrogenic potential of mesenchymal
stromal cells in treating fibrosis in Crohn's Disease. Dig Dis Sci.
63:1821–1834. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Feagan BG, Rutgeerts P, Sands BE, Hanauer
S, Colombel JF, Sandborn WJ, Van Assche G, Axler J, Kim HJ, Danese
S, et al: Vedolizumab as induction and maintenance therapy for
ulcerative colitis. N Engl J Med. 369:699–710. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Franke A, Balschun T, Karlsen TH,
Sventoraityte J, Nikolaus S, Mayr G, Domingues FS, Albrecht M,
Nothnagel M, Ellinghaus D, et al: Sequence variants in IL10, ARPC2
and multiple other loci contribute to ulcerative colitis
susceptibility. Nat Genet. 40:1319–1323. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Cohen P, Pagnoux C, Mahr A, Arène JP,
Mouthon L, Le Guern V, André MH, Gayraud M, Jayne D, Blöckmans D,
et al: Churg-Strauss syndrome with poor-prognosis factors: A
prospective multicenter trial comparing glucocorticoids and six or
twelve cyclophosphamide pulses in forty-eight patients. Arthritis
Rheum. 57:686–693. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Lichtenstein GR, Diamond RH, Wagner CL,
Fasanmade AA, Olson AD, Marano CW, Johanns J, Lang Y and Sandborn
WJ: Clinical trial: Benefits and risks of immunomodulators and
maintenance infliximab for IBD-subgroup analyses across four
randomized trials. Aliment Pharmacol Ther. 30. pp. 210–226. 2009,
View Article : Google Scholar
|
|
39
|
Vetter M and Neurath MF: Treatment
perspectives in Crohn's disease. Digestion. 98:135–142. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Geng CA, Yang TH, Huang XY, Yang J, Ma YB,
Li TZ, Zhang XM and Chen JJ: Anti-hepatitis B virus effects of the
traditional Chinese herb Artemisia capillaris and its active
enynes. J Ethnopharmacol. 224:283–289. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Sun J, Shen X, Dong J, Wang H, Zuo L, Zhao
J, Zhu W, Li Y, Gong J and Li J: Tripterygium wilfordii Hook F as
maintenance treatment for Crohn's disease. Am J Med Sci.
350:345–351. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Izutani R, Loh EY, Reinecker HC, Ohno Y,
Fusunyan RD, Lichtenstein GR, Rombeau JL and Macdermott RP:
Increased expression of interleukin-8 mRNA in ulcerative colitis
and Crohn's disease mucosa and epithelial cells. Inflamm Bowel Dis.
1:37–47. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Fine SN: Adalimumab for the treatment of
fistulas in patients with Crohn's disease. Inflamm Bowel Dis.
17:667–668. 2011. View Article : Google Scholar
|
|
44
|
Peyrin-Biroulet L, Oussalah A, Williet N,
Pillot C, Bresler L and Bigard MA: Impact of azathioprine and
tumour necrosis factor antagonists on the need for surgery in newly
diagnosed Crohn's disease. Gut. 60:930–936. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Bamias G and Cominelli F: Cytokines and
intestinal inflammation. Curr Opin Gastroenterol. 32:437–442. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Lawrence T and Fong C: The resolution of
inflammation: Anti-inflammatory roles for NF-kappaB. Int J Biochem
Cell Biol. 42:519–523. 2010. View Article : Google Scholar
|
|
47
|
Han YM, Koh J, Kim JW, Lee C, Koh SJ, Kim
B, Lee KL, Im JP and Kim JS: NF-kappa B activation correlates with
disease phenotype in Crohn's disease. PLoS One. 12:e01820712017.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Karin M: Mitogen activated protein kinases
as targets for development of novel anti-inflammatory drugs. Ann
Rheum Dis. 63(Suppl 2): ii62–ii64. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Cuadrado A and Nebreda AR: Mechanisms and
functions of p38 MAPK signaling. Biochem J. 429:403–417. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Peroval MY, Boyd AC, Young JR and Smith
AL: A critical role for MAPK signaling pathways in the
transcriptional regulation of toll like receptors. PLoS One.
8:e512432013. View Article : Google Scholar
|
